Dual Antiplatelet Therapy Market : Antibiotic Treatment Segment to Lead Global Market by 2031

Dual antiplatelet therapy is defined as the use of aspirin and P2Y12 receptor inhibitor to prevent blood clotting, and through a double mechanism, it prevents thrombotic complications. The dual antiplatelet therapy is often prescribed for patients who had a cardiac attack, had coronary artery bypass graft surgery (CABG), or were treated with stents in coronary arteries. Growing prevalence of cardiovascular disease on the coattails of changing lifestyles habits is expected to be a key factor influencing the development of dual antiplatelet therapy market. Government initiatives in healthcare infrastructures, especially in emerging economies have favored the adoption of advanced methods of treatment which in turn is likely to create potential growth prospects of dual antiplatelet therapy market in these regions.

This Press Release will help you to understand the market Statistics of European Region.

Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at @ https://www.factmr.com/connectus/sample?flag=S&rep_id=1002

Although the dual antiplatelet therapy reduces the risks of thromboembolic conditions, it is also associated with a major risk of bleeding that can sometimes be fatal, which may create hindrance in the growth of dual antiplatelet therapy market. Emergence of more effective oral and other anticoagulants may also hamper the market growth. In addition, high cost associated with the therapy and lack of its awareness in various regions across the globe will possibly confine the growth of dual antiplatelet therapy market.

Platelets are small blood particles that clump together to form clots. Sometimes, these clots may lead to myocardial infarction or a sudden blockage in the coronary artery. Antiplatelets are a class of drugs that inhibit blood clot formation. Many heart attack and stroke patients are treated with two types of antiplatelet drugs to prevent blood clotting. This is known as dual antiplatelet therapy. Dual antiplatelet therapy is a combination therapy which utilizes two antiplatelet drugs.

One of the drugs in dual antiplatelet therapy is aspirin. Patients who have coronary artery disease, heart attack, coronary artery bypass surgery or stents are treated with aspirin for the rest of their life. The second drug in dual antiplatelet therapy is a P2Y12 inhibitor – either clopidogrel, pasugrel, or ticagrelor. Dual antiplatelet therapy leads to greater platelet inhibition than what is achieved by aspirin alone, thus, decreasing the likelihood of future blood clot formations in the coronary arteries and heart attacks.

To receive extensive list of important regions, ask for TOC here@ https://www.factmr.com/connectus/sample?flag=T&rep_id=1002

Dual Antiplatelet Therapy Market: Segmentation

Tentatively, the global dual antiplatelet therapy market can be segmented on the basis of product type, indication, distribution channel, and geography.

Based on product type, the global dual antiplatelet therapy market is segmented as:
• Aspirin
• Clopidogel
• Prasugrel
• Ticagrelor

Based on indications, the global dual antiplatelet therapy market is segmented as:
• Myocardial Infarction
• Stable Ischemic Heart Disease
o Bare-metal stent (BMS)
o Drug-Eluting Stent (DES)
o Coronary Artery Bypass Graft Surgery (CABG)
• Acute Coronary Syndromes
o Fibrinolysis
o Percutaneous Coronary Artery Intervention

Based on distribution channel, the global Dual Antiplatelet Therapy Market is segmented as:
• Hospital Pharmacies
• Independent Pharmacies
• Retail Pharmacies
• Online Pharmacy

Based on geography, the global Antiplatelet Therapy Market is segment as:
• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific Excluding Japan
• Japan
• Middle-East & Africa

Pre-Book Right Now for Exclusive Analyst Support @ https://www.factmr.com/checkout/1002/S

Dual Antiplatelet Therapy Market: Key Players

The global market for dual antiplatelet therapy is highly fragmented. Examples of some of the key players operating in the global dual antiplatelet therapy market are Bayer AG, Novacap, Shiono Chemical Co., Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Dr. Reddy's Laboratories, Eli Lilly & Co. Ltd. and others.

Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
E: sales@factmr.com
Website: https://www.factmr.com
Research Insight: https://www.factmr.com/report/1002/dual-antiplatelet-therapy-market

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.